Viatris has commenced a tender offer to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash. The offer expires Nov. 16, 2026, and is conditioned on a majority of shares being tendered and antitrust clearance. Pacira's board unanimously recommends that stockholders tender their shares. The transaction is structured under Delaware law Section 251(h), so no stockholder vote is required.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
